Overview

Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia

Status:
Recruiting
Trial end date:
2024-08-30
Target enrollment:
Participant gender:
Summary
This research study is studying an immunotherapy drug, as a possible treatment for oral proliferative verrucous leukoplakia (OPVL).
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Bristol-Myers Squibb
Treatments:
Antibodies, Monoclonal
Nivolumab